TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9023068

Group type: EXPERIMENTAL
Intervention: Individual Drug Counseling (IDC)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Cognitive sessions
Number of subjects: 62

Group type: COMPARATOR
Intervention: Supportive Expressive psychodynamic sessions
Number of subjects: 62
Study: 2054266

Group type: EXPERIMENTAL
Intervention: Plain paracetamol tablets 1000 mg every 6th hour
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Paracetamol slow-release tablets 2000 mg every 12th hour
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 6666216

Group type: EXPERIMENTAL
Intervention: 60 mg orally administered ISDN
Number of subjects: 509

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 509
Study: 31398634

Group type: EXPERIMENTAL
Intervention: Oculo-motor exercises (six sessions per week for four weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (daily routine exercises)
Number of subjects: 30
Study: 28816293

Group type: EXPERIMENTAL
Intervention: 45S5 bioactive glass
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (powder of zinc oxide)
Number of subjects: 18
Study: 25420474

Group type: EXPERIMENTAL
Intervention: Magnetic seizure therapy (MST)
Number of subjects: 26
Study: 23337174

Group type: EXPERIMENTAL
Intervention: 1 mg glucagon
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 21763935

Group type: EXPERIMENTAL
Intervention: Rilpivirine 25 mg once daily
Number of subjects: 680

Group type: COMPARATOR
Intervention: Efavirenz 600 mg once daily
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Rilpivirine
Number of subjects: 680

Group type: COMPARATOR
Intervention: Efavirenz
Number of subjects: 680
Study: 19247280

Group type: EXPERIMENTAL
Intervention: Nutrition (N; n = 21)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Nutrition + Strength training (N+ST; n = 17)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control (C; n = 16)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: All intervention groups
Number of subjects: 54
Study: 16377364

Group type: EXPERIMENTAL
Intervention: Medical termination (with mifepristone)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Surgical termination
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both medical and surgical termination
Number of subjects: 200
Study: 15257922

Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiation therapy combined with concomitant chemotherapy
Number of subjects: 70

Group type: COMPARATOR
Intervention: Chemotherapy only
Number of subjects: 70
Study: 11571882

Group type: EXPERIMENTAL
Intervention: High-tech surgical treatment modalities
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo surgery
Number of subjects: 0
Study: 9223690

Group type: EXPERIMENTAL
Intervention: Oral antibiotic
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IM ceftriaxone
Number of subjects: 0

Group type: COMPARATOR
Intervention: No antibiotic
Number of subjects: 0
Study: 7686707

Group type: EXPERIMENTAL
Intervention: HT-HES (7.5% NaCl/10% hydroxyethyl starch 200.000/0.5)
Number of subjects: 37

Group type: COMPARATOR
Intervention: HES (0.9% NaCl/10% hydroxyethyl starch 200.000/0.5)
Number of subjects: 37
Study: 3639536

Group type: EXPERIMENTAL
Intervention: Teaching intervention based on the Brazelton Neonatal Behavioral Assessment Scale
Number of subjects: 46

Group type: COMPARATOR
Intervention: Newborn Information Checklist about infant behavior
Number of subjects: 46

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 46
Study: 31597014

Group type: EXPERIMENTAL
Intervention: 20 mg monophasic controlled-release oxycodone tablets
Number of subjects: 15

Group type: COMPARATOR
Intervention: 10 mg oral solution oxycodone
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Controlled-release formulations (both 20 mg tablets)
Number of subjects: 15
Study: 29945259

Group type: EXPERIMENTAL
Intervention: Herbal formulations (shampoo and solution)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Concomitant use of shampoo and solution
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 28631745

Group type: EXPERIMENTAL
Intervention: Manual ISNCSCI worksheets
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Errors in manual ISNCSCI worksheets
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Panel errors in ISNCSCI classification
Number of subjects: 184
Study: 26228675

Group type: EXPERIMENTAL
Intervention: Fenofibrate (160 mg/d)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Extended-release niacin (0.5 g/d for 3 wk, then 1 g/d)
Number of subjects: 66
Study: 23698241

Group type: EXPERIMENTAL
Intervention: Heavy-resistance training
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Plyometric plus heavy-resistance training
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Plyometric resistance training
Number of subjects: 50
Study: 21802126

Group type: EXPERIMENTAL
Intervention: 300 IR 5-grass-pollen SLIT tablets (Oralair) for 2 months
Number of subjects: 633

Group type: EXPERIMENTAL
Intervention: 300 IR 5-grass-pollen SLIT tablets (Oralair) for 4 months
Number of subjects: 633

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 633
Study: 18285392

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.6 microg kg(‐1)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 40
Study: 17138173

Group type: EXPERIMENTAL
Intervention: 2 mL of 4% articaine/HCl with 1:100,000 epinephrine injected into the buccal vestibule of the tooth
Number of subjects: 53

Group type: COMPARATOR
Intervention: Palatal injection
Number of subjects: 53
Study: 14650862

Group type: EXPERIMENTAL
Intervention: Fondaparinux (2.5 mg once daily for 21 +/- 2 days)
Number of subjects: 656

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 656

Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 656

Group type: COMPARATOR
Intervention: Fondaparinux and Placebo
Number of subjects: 656
Study: 15508780

Group type: EXPERIMENTAL
Intervention: Chloroquine (n = 42)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Sulfadoxine/pyrimethamine (n = 30)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Combined treatment (n = 32)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Combined treatment
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 104
Study: 10937957

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 8572358

Group type: EXPERIMENTAL
Intervention: Epinephrine 7.5 micrograms
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Epinephrine 15 micrograms
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Epinephrine 30 micrograms
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (intravenous saline)
Number of subjects: 36
Study: 1716334

Group type: EXPERIMENTAL
Intervention: ProMACE/MOPP protocol
Number of subjects: 81

Group type: COMPARATOR
Intervention: ProMACE/MOPP
Number of subjects: 81

Group type: COMPARATOR
Intervention: MACOP-B
Number of subjects: 81
Study: 6666224

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (80 mg once daily)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (80 mg twice daily)
Number of subjects: 22
Study: 30311214

Group type: EXPERIMENTAL
Intervention: LCPUFA supplementation (0.32%, 0.64%, or 0.96% of total fatty acids)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: LCPUFA supplementation (0.64%)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: LCPUFA supplementation (0.32% and 0.64%)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: LCPUFA groups
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (no LCPUFA)
Number of subjects: 42
Study: 29277316

Group type: EXPERIMENTAL
Intervention: FLEX adaptive behavioral intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 0
Study: 27133722

Group type: EXPERIMENTAL
Intervention: Family Navigation (FN)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual Care (C)
Number of subjects: 40
Study: 24893903

Group type: EXPERIMENTAL
Intervention: Cognitive remediation (CR) integrated into a supported education program
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Cognitive remediation (CR)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Supported education without CR
Number of subjects: 37
Study: 22762958

Group type: EXPERIMENTAL
Intervention: Fagerström Tolerance Questionnaire for Smokeless Tobacco (FTQ‐ST)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Severson Smokeless Tobacco Dependency Scale (SSTDS)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Glover‐Nilsson Smokeless Tobacco Behavioral Questionnaire (GN‐STBQ)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: All scales (FTQ‐ST, SSTDS, GN‐STBQ)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: SSTDS
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: FTQ‐ST and GN‐STBQ
Number of subjects: 225
Study: 20077492

Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid (5-ALA) at a dosage of 5 mg/kg body weight administered prior to surgery
Number of subjects: 0
Study: 17050563

Group type: EXPERIMENTAL
Intervention: Inhalation of 25 mg alpha(1)-antitrypsin (AAT) daily for 4 weeks
Number of subjects: 52
Study: 16262741

Group type: EXPERIMENTAL
Intervention: Artesunate (4 mg/kg daily for 3 days) plus Amodiaquine (30 mg/kg over 3 days)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Chloroquine (25 mg/kg over 3 days) plus Pyrimethamine-Sulfadoxine (25 mg/kg of sulfadoxine at presentation)
Number of subjects: 153
Study: 12122508

Group type: EXPERIMENTAL
Intervention: Selective decontamination of the digestive tract (SDD), started at least 7 days before transplantation (n=15)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (n=16)
Number of subjects: 31
Study: 9802119

Group type: EXPERIMENTAL
Intervention: Combined cognitive-behavioral and pharmacological therapy (fluoxetine for AN-R and AN-BP, amineptine for AN-BP and BN, fluvoxamine for BN)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (healthy age- and sex-matched controls)
Number of subjects: 26
Study: 7697236

Group type: EXPERIMENTAL
Intervention: Mouthpiece breathing with noseclip
Number of subjects: 6

Group type: COMPARATOR
Intervention: No mouthpiece and noseclip (control)
Number of subjects: 6
Study: 2506671

Group type: EXPERIMENTAL
Intervention: Heparin treatment (subcutaneously administered clinical grade heparin)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Nitrates and calcium-channel blockers without heparin
Number of subjects: 2
Study: 742831

Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Methoxyflurane
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Combined analgesic-relaxant anaesthesia
Number of subjects: 72

Group type: COMPARATOR
Intervention: Epidural anaesthesia
Number of subjects: 72
Study: 30203748

Group type: EXPERIMENTAL
Intervention: Glucosamine hydrochloride tablets
Number of subjects: 130

Group type: COMPARATOR
Intervention: Cervical vertebra exercises and cervical occipital belt traction therapy (reference group)
Number of subjects: 130
Study: 28918310

Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study: 26461996

Group type: EXPERIMENTAL
Intervention: Early physical therapy (4 sessions)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Usual care (no additional interventions)
Number of subjects: 220
Study: 24107292

Group type: EXPERIMENTAL
Intervention: Pitolisant (10 mg, 20 mg, or 40 mg a day)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Modafinil (100 mg, 200 mg, or 400 mg a day)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 21396086

Group type: EXPERIMENTAL
Intervention: Daily oral tablet containing 1 mg vitamin B12
Number of subjects: 200

Group type: COMPARATOR
Intervention: Matching placebo tablet
Number of subjects: 200
Study: 18285604

Group type: EXPERIMENTAL
Intervention: Postmastectomy radiotherapy (PMRT)
Number of subjects: 1000
Study: 16516359

Group type: EXPERIMENTAL
Intervention: Patellar resurfacing
Number of subjects: 47

Group type: COMPARATOR
Intervention: No patellar resurfacing
Number of subjects: 47
Study: 14499225

Group type: EXPERIMENTAL
Intervention: Early discharge strategy (pharmacological stress echocardiography on day 3-5)
Number of subjects: 458

Group type: COMPARATOR
Intervention: Usual care strategy (clinical evaluation with hospital discharge on day 7-9 and symptom-limited post-discharge exercise electrocardiography)
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: Early discharge strategy
Number of subjects: 458

Group type: COMPARATOR
Intervention: Usual care strategy
Number of subjects: 458
Study: 11758131

Group type: EXPERIMENTAL
Intervention: Standard dose nebulized albuterol (0.15 mg/kg)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Low dose nebulized albuterol (0.075 mg/kg) plus ipratropium-bromide (250 micrograms/dose)
Number of subjects: 29
Study: 9390958

Group type: EXPERIMENTAL
Intervention: CHO (0.75 g/kg) + Pro (0.1 g/kg) + Fat (0.02 g/kg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: CHO (1 g/kg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (Pl; artificial sweetener)
Number of subjects: 16
Study: 8426322

Group type: EXPERIMENTAL
Intervention: Subconjunctival injection of gentamicin and dexamethasone
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Collagen shield soaked in gentamicin and dexamethasone
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Collagen shield without drug
Number of subjects: 61
Study: 3624680

Group type: EXPERIMENTAL
Intervention: mPEG-modified honeybee venom (200 micrograms maintenance dose)
Number of subjects: 35

Group type: COMPARATOR
Intervention: unmodified honeybee venom (100 micrograms maintenance dose)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: mPEG-modified honeybee venom
Number of subjects: 35

Group type: COMPARATOR
Intervention: unmodified honeybee venom
Number of subjects: 35
Study: 1694913

Group type: EXPERIMENTAL
Intervention: Metoprolol (100-300 mg/day)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Pindolol (5-15 mg/day)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Pindolol and Metoprolol
Number of subjects: 45
Study: 4573205

Group type: EXPERIMENTAL
Intervention: Vitamin D treatment in epileptic patients
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo treatment in epileptic patients
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Vitamin D treatment in normal subjects
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo treatment in normal subjects
Number of subjects: 43
Study: 31367742

Group type: EXPERIMENTAL
Intervention: Omadacycline
Number of subjects: 1380

Group type: COMPARATOR
Intervention: Linezolid
Number of subjects: 1380
Study: 28258505

Group type: EXPERIMENTAL
Intervention: Decision aid
Number of subjects: 120

Group type: COMPARATOR
Intervention: Fact sheet
Number of subjects: 120
Study: 26156739

Group type: EXPERIMENTAL
Intervention: rs16147 C allele
Number of subjects: 723

Group type: EXPERIMENTAL
Intervention: High-fat diet
Number of subjects: 723

Group type: EXPERIMENTAL
Intervention: rs16147 T allele
Number of subjects: 723
Study: 22835079

Group type: EXPERIMENTAL
Intervention: Parecoxib (80 mg)
Number of subjects: 0
Study: 21076089

Group type: EXPERIMENTAL
Intervention: Positron emission mammography (PEM)
Number of subjects: 388

Group type: COMPARATOR
Intervention: Magnetic resonance (MR) imaging
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Combination of PEM and MR imaging
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: PEM
Number of subjects: 388

Group type: COMPARATOR
Intervention: MR imaging
Number of subjects: 388
Study: 19259859

Group type: EXPERIMENTAL
Intervention: ASL cervical cancer education video
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 130
Study: 17277641

Group type: EXPERIMENTAL
Intervention: TrP palpation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Spontaneous electromyographic activity
Number of subjects: 20
Study: 12500005

Group type: EXPERIMENTAL
Intervention: Probiotic therapy in combination with Oral Rehydration Solution (ORS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo in combination with Oral Rehydration Solution (ORS)
Number of subjects: 0
Study: 10389785

Group type: EXPERIMENTAL
Intervention: Ketamine 75 microg/kg IV
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Ketamine 100 microg/kg IV
Number of subjects: 140
Study: 8557897

Group type: EXPERIMENTAL
Intervention: Nitroglycerin infusion (0.5 micrograms/kg body weight per min) for 24 hours
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Nitroglycerin infusion (0.5 micrograms/kg body weight per min) for 72 hours
Number of subjects: 28

Group type: COMPARATOR
Intervention: Nitroglycerin infusion (0.5 micrograms/kg body weight per min) for 0 hours (control group)
Number of subjects: 28
Study: 1988573

Group type: EXPERIMENTAL
Intervention: Vincristine, cytarabine, and dexamethasone (VADx)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Daunorubicin, cytarabine, and thioguanine (DAT)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Standard two‐cycle therapy
Number of subjects: 256

Group type: COMPARATOR
Intervention: Four‐cycle regimen
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Best induction/continuation therapy combination
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Four‐cycle continuation therapy
Number of subjects: 256
Study: 6409493

Group type: EXPERIMENTAL
Intervention: Kinetically based chemotherapy regimen before and after radiotherapy
Number of subjects: 86

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 86
Study: 31028124

Group type: EXPERIMENTAL
Intervention: Neuropalliative care
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 60
Study: 28656073

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) (>90% maximum heart rate)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Training (MICT) (70% maximum heart rate)
Number of subjects: 27
Study: 25130281

Group type: EXPERIMENTAL
Intervention: Mirabegron 50 mg once daily
Number of subjects: 1126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1126

Group type: COMPARATOR
Intervention: Tolterodine ER 4 mg once daily
Number of subjects: 1126
Study: 22476168

Group type: EXPERIMENTAL
Intervention: Beta-alanine (BA) supplementation 4 g·d(‐1) for 1 week, then 6 g·d(‐1) for 4 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 21
Study: 22104710

Group type: EXPERIMENTAL
Intervention: Intranasal citrate (0.3 M solution)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intranasal citrate with 2% lidocaine pretreatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intranasal citrate mixed with 2% lidocaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (IN saline)
Number of subjects: 0
Study: 19323926

Group type: EXPERIMENTAL
Intervention: Rapid group (directly to catheterization laboratory)
Number of subjects: 546

Group type: COMPARATOR
Intervention: Non-rapid group (admitted to CCU or cardiac ward first)
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Rapid group
Number of subjects: 546

Group type: COMPARATOR
Intervention: Non-rapid group
Number of subjects: 546
Study: 16782393

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 0
Study: 15462108

Group type: EXPERIMENTAL
Intervention: Irbesartan (150 mg once daily)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fosinopril (20 mg once daily)
Number of subjects: 30
Study: 10877199

Group type: EXPERIMENTAL
Intervention: Oral 17beta-estradiol 2 mg daily with sequential oral norethindrone acetate (NETA) 1 mg daily from days 12 to 22
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Transdermal 17beta-estradiol 0.05 mg daily with sequential oral NETA 1 mg daily from days 17 to 28
Number of subjects: 42
Study: 9099116

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural counselling (6 sessions)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Cognitive-behavioural counselling (1 session)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 1526057

Group type: EXPERIMENTAL
Intervention: Budesonide 400 micrograms
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Budesonide 800 micrograms
Number of subjects: 59
Study: 3842217

Group type: EXPERIMENTAL
Intervention: Nova T
Number of subjects: 400

Group type: COMPARATOR
Intervention: MLCu250
Number of subjects: 400
Study: 30901496

Group type: EXPERIMENTAL
Intervention: Diploid genotypes under low-water availability treatment
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Hexaploid genotypes under low-water availability treatment
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Both diploid and hexaploid genotypes under temperature and watering treatments
Number of subjects: 2

Group type: COMPARATOR
Intervention: Water availability treatment
Number of subjects: 2

Group type: COMPARATOR
Intervention: Temperature treatment
Number of subjects: 2
Study: 29498786

Group type: EXPERIMENTAL
Intervention: Intraperitoneal warm saline and pulmonary recruitment manoeuvre
Number of subjects: 200

Group type: COMPARATOR
Intervention: Gentle abdominal pressure (Control)
Number of subjects: 200
Study: 28361570

Group type: EXPERIMENTAL
Intervention: 3‐cm elastic cuff inflated to 160 mmHg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 5‐cm nylon cuff inflated to 40% of arterial occlusion pressure
Number of subjects: 15
Study: 25255696

Group type: EXPERIMENTAL
Intervention: Immediate home modifications (treatment group)
Number of subjects: 842

Group type: COMPARATOR
Intervention: 3-year wait before modifications (control group)
Number of subjects: 842
Study: 23178035

Group type: EXPERIMENTAL
Intervention: (18)F‐flutemetamol PET and MRI
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: (18)F‐flutemetamol PET
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Combination of amyloid PET and MTA data
Number of subjects: 72
Study: 21951559

Group type: EXPERIMENTAL
Intervention: Neuromuscular training program for 8 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sports brace worn during all sports activities for 1 year
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of neuromuscular training program for 8 weeks and sports brace worn during all sports activities for 1 year
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 0